The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
Open accessAbstract
Genetically engineered, neuroattenuated herpes simplex viruses (HSVs) expressing various cytokines can improve survival when used in the treatment of experimental brain tumors. These attenuated viruses have both copies of γ 1 34.5 deleted. Recently, we demonstrated increased survival of C57BL/6 mice bearing syngeneic GL-261 gliomas when treated with an engineered HSV expressing IL-4, as compared with treatment with the parent construct (γ 1 34.5−) alone or with a virus expressing IL-10. Herein, we report construction of a conditionally replication-competent mutant expressing both subunits of mIL-12 (M002) and its evaluation in a syngeneic neuroblastoma murine model. IL-12 induces a helper T cell subset type 1 response, which may induce more durable antitumor effects.In vitro studies showed that, when infected with M002, both Vero cells and murine Neuro-2a neuroblastoma cells produced physiologically relevant levels of IL-12 heterodimers, as determined by ELISA. M002 was cytotoxic for Neuro-2a cells and human glioma cell lines U251MG and D54MG. Neurotoxicity studies, as defined by plaque-forming units/LD 50, performed in HSV-1-sensitive A/J strain mice found that M002 was not toxic even at high doses. When evaluated in an intracranial syngeneic neuroblastoma murine model, median survival of M002-treated animals was significantly longer than the median survival of animals treated with R3659, the parent γ 1 34.5−mutant lacking any cytokine gene insert. Immunohistochemical analysis of M002-treated tumors identified a pronounced influx of CD4+T cells and macrophages as well as CD8+cells when compared with an analysis of R3659-treated tumors. We conclude that M002 produced a survival benefit via oncolytic effects combined with immunologic effects meditated by helper T cells of subset type 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Chou, J., Kern, E. R., Whitley, R. J., & Roizman, B. (1990) · Science · doi:10.1126/science.2173860 · Cited by 711
Self-citationCloning and expression of murine IL-12
Schoenhaut, D. S., Chua, A. O., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., McComas, W., Familletti, P. C., Gately, M. K., & Gubler, U. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3433 · Cited by 470
Post, L. E., & Roizman, B. (1981) · Cell · doi:10.1016/0092-8674(81)90247-6 · Cited by 336
Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6466 · Cited by 271
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.
Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., & Chen, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11302 · Cited by 227
Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., & Whitley, R. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1411 · Cited by 192
Self-citationBramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.16-1995 · Cited by 188
Markert, J. M., Malick, A., Coen, D. M., & Martuza, R. L. (1993) · Neurosurgery · doi:10.1097/00006123-199304000-00016 · Cited by 187
Self-citation
Cited by
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Self-citationMarkert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.228 · Cited by 401
Self-citationImmunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208
Metadata
- Authors
- Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-02-18
- Volume
- 97
- Issue
- 5
- Pages
- 2208-2213
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2098738104
- Cited by
- 332
- References
- 27
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. https://app.cochat.ai/papers/10.1073/pnas.040557897
- The paper
- Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.040557897
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.